Fmoc-AAGIGILTV-OH

Ref. 3D-PP47642

Informations sur le produit

• Nom: Fmoc-AAGIGILTV-OH

Description

Peptide Fmoc-AAGIGILTV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Fmoc-AAGIGILTV-OH include the following: Rational design of peptide-based tumor vaccines WS Meng , LH Butterfield - Pharmaceutical research, 2002 - Springerhttps://link.springer.com/article/10.1023/A:1016497818471 Induction of melanoma-reactive CTL in HLA-A* 0201/K b transgenic mice by vaccination with peptides derived from MAGE-2 and MART-1 RPM Sutmuller, SH van der Burg , MJW Visseren - Immunology , 1997 - infona.plhttps://www.infona.pl/resource/bwmeta1.element.elsevier-b8764d78-8174-3548-9e3e-5a5b831cf1f6 Fluorescence labeling of anchor-modified Mart-1 peptide for increasing its affinity for HLA-A* 0201: Hit two targets with one arrow P Fattahi, N Salehi , Z Azizi - Journal of Peptide , 2023 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3480 Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes MJ Maeurer , HW Chan, J Karbach - European journal of , 1996 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830261112 Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue MJ Maeurer , A Necker, RD Salter - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.1580 Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines LH Brinckerhoff, VV Kalashnikov - journal of cancer, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19991029)83:3%3C326::AID-IJC7%3E3.0.CO;2-X Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A JN Cormier, ML Salgaller, T Prevette - The cancer journal , 1997 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597550/ Mass-spectrometric evaluation of HLA-A* 0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100 JCA Skipper, PH Gulden - journal of cancer, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19990827)82:5%3C669::AID-IJC9%3E3.0.CO;2-%23 Detection of antigen-specific T-cells with MHC/peptide-tetramer-complexes G Tully, E Jager, MJ Maeurer - Clinical and Applied Immunology Reviews, 2002 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1529104902000569 MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A* 0201-restricted, Melan-A-derived peptide after active intracellular processing G Held, A Wadle, N Dauth - European journal of , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.200636545 TCR-induced alteration of primary MHC peptide anchor residue F Madura, PJ Rizkallah , M Legut - European journal of , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.201948085 Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading E Ranieri , LS Kierstead, H Zarour - Immunological , 2000 - Taylor & Francishttps://www.tandfonline.com/doi/pdf/10.3109/08820130009062294 Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type E Jaeger, R Salter, C Castelli, H Höhn - The Journal of , 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/168/6/2766/34711 Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8 T cells using HLA-A2 E Jager, R Salter, C Castelli, H Höhn, K Freitag - J. Immunol, 2002 - academia.eduhttps://www.academia.edu/download/47681918/Impact_of_antigen_presentation_on_TCR_mo20160731-32057-yvft53.pdf Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A E Jager, H Höhn, J Karbach, F Momburg - journal of cancer, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19990611)81:6%3C979::AID-IJC22%3E3.0.CO;2-Y Peptide-specific CD8+ T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-1 E Jager, H Höhn, A Necker, R Förster - journal of cancer, 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.10165 Diversity of the fine specificity displayed by HLA-A* 0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide D Valmori, N Gervois, D Rimoldi - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/12/6956/1064 Structural and functional characterization of peptide-beta2m fused HLA-A2/MART127-35 complexes C Shen, CC Chang, J Zhang, W Guo, L Xia - Biochemical and , 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006291X06001999 Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes C Pinilla , V Rubio-Godoy, V Dutoit , P Guillaume - Cancer Research, 2001 - AACRhttps://aacrjournals.org/cancerres/article-abstract/61/13/5153/507515 Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells C Douat-Casassus, N Marchand-Geneste - Journal of medicinal , 2007 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm0613368 Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A* 0201-binding peptides from the Melan-A/MART A van Elsas , SH van der Burg - European journal of , 1996 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830260803 Allogeneic Cell Therapy with Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Malignant Melanoma A Nolte, J Slotty, C Beike, WE Berdel - in Hematology and , 2003 - Springerhttps://link.springer.com/chapter/10.1007/978-3-642-55774-3_5 Stability and CTL activity of N-terminal glutamic acid containing peptides A Beck , MC Bussat, C Klinguer-Hamour - Journal of Peptide , 2001 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-3011.2001.00895.x Peptide-based strategies for targeted tumor treatment and imaging A Ayo, P Laakkonen - Pharmaceutics, 2021 - mdpi.comhttps://www.mdpi.com/1999-4923/13/4/481

• Marque: Biosynth